An Open-label, Phase I, Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY87-2243 Given Once Daily in Subjects With Advanced Malignancies
Trial Snapshot
- Phase
- Phase 1
- Status
- Terminated
- Sponsor
- Bayer
- Enrollment
- 5
- Primary Endpoint
- Frequency of adverse events
Study Overview
Brief Summary
This is the first study of this drug in human beings. Every patient will receive the drug, there is no placebo group. Patients with advanced tumors will be treated. Different groups of patients will receive different dosages to determine the safety and maximum tolerated dose (MTD) of BAY87-2243. The study will also assess how the drug is metabolized by the body, its biologic effects in the body, and changes in tumor size.
BAY87-2243 will be given as a tablet which dissolves in the gut. Based on findings from this study it may be later given as a tablet which dissolves in the stomach.
BAY87-2243 will be given per mouth, once a day, every day. Treatment will stop if the tumor continues to grow, if side effects occur which the patient can not tolerate or if the patients decides to exit treatment.
The study will be conducted in 3 - 4 centers in 3 countries (Norway, United Kingdom and Germany). The study will have a part where doses are escalated in different groups of patients. Each dose level will be evaluated in a new group of 3 - 6 subjects. This will be followed by an extension part where patients are treated at the highest tolerable dose in groups of up to 25 patients. The extension part will be described in an amendment to the study protocol later. The number of subjects estimated for this study will depend on the number of groups enrolled. The starting dose will be 5 mg given orally as a tablet formulation.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Male or female subjects aged >/= 18 years
- •Subjects with advanced, histologically or cytologically confirmed solid tumors, refractory to any standard therapy, have no standard therapy available, or subjects must have actively refused any treatment which would be regarded standard, and / or if in the judgement of the investigator, experimental treatment is clinically and ethically acceptable
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2
- •Life expectancy of at least 3 month
- •Adequate bone marrow, liver, and renal functions
Exclusion Criteria
- •History of cardiac disease including congestive heart failure > NYHA (New York Heart Association) II, unstable angina (anginal symptoms at rest), or new-onset angina (within the past 3 months) or myocardial infarction within the past 6 months and cardiac arrhythmias requiring anti-arrhythmic therapy except for beta-blockers and digoxin
- •History of ischemic cardiovascular disease
- •Family history of long QT syndrome
- •Persistent hypokalemia < 3.5 mmol/L
- •History of cerebral ischemia including transient ischemic attack (TIA), prolonged reversible ischemic neurologic deficit (PRIND), and ischemic stroke within the past 6 months
- •Known alcohol abuse
- •Moderate or severe hepatic impairment, i.e. Child-Pugh class B or C
- •Diabetes mellitus treated with oral antidiabetics or insulin
- •History of human immunodeficiency virus (HIV) infection or chronic hepatitis B or C
- •Active clinically serious infections of CTCAE > Grade 2 (Common Terminology Criteria for Adverse Events v4.02)
- •Symptomatic metastatic brain or meningeal tumors unless the subject is > 6 months from definitive therapy, has no evidence of tumor growth on an imaging study within 4 weeks prior to study entry, and is clinically stable with respect to the tumor at the time of study entry.
- •Unresolved specific chronic toxicity CTCAE > Grade 2
- •Subjects may not receive potent inducers of CYP3A4, such as phenytoin, carbamazepine, and rifampicin, as the oral clearance of ondansetron may increase and ondansetron plasma concentrations may decrease due to antiemetic regimen
- •Concomitant medication with metformin
- •Concomitant medication with drugs known to prolong the QT interval
- •Relevant pathological changes in the ECG such as a second or third-degree AV block, prolongation of the QRS complex over 120 ms or of the QT / QTc-interval over 450 ms in men and women
Arms & Interventions
Arm 1
Intervention: BAY87-2243 (Drug)
Outcomes
Primary Outcomes
Frequency of adverse events
Time Frame: Up to 3 years or longer if indicated
Maximum tolerated dose, measured by adverse event profile
Time Frame: Up to 3 years or longer if indicated
Secondary Outcomes
- Plasma concentrations of BAY87-2243, measured by Cmax, tmax, AUC(0-tn), AUC and half-life(Up to 3 years or longer if indicated)
- Biomarkers evaluation (analysis of carbonic anhydrase 9 and VEGF in plasma)(Up to 3 years or longer if indicated)
- Tumor response evaluation based on RECIST 1.1 every 2 cycles(Up to 3 years or longer if indicated)